Literature DB >> 20230579

Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document.

D M Vail1, G M Michels, C Khanna, K A Selting, C A London.   

Abstract

Standardized assessment of response to therapy for lymphoma in dogs is lacking, making critical comparisons of treatment protocols difficult. This Veterinary Cooperative Oncology Group (VCOG) consensus document, based on the recommendations of a subcommittee of ACVIM board-certified veterinary oncologists, was unanimously adopted at the 29th Annual Conference of the Veterinary Cancer Society (VCS) by the VCOG membership. It has integrated guidance from the response assessment criteria established for lymphoma in human patients using standards available in routine veterinary oncology practices that are simple, repeatable and consistently applicable. These guidelines are intended only for use in dogs, where peripheral lymphadenopathy represents the principal component of their disease and as such do not critically assess extranodal disease (e.g., primary cutaneous, central nervous system, gastrointestinal). It is hoped these guidelines will be widely adopted and serve to facilitate the comparison of current and future treatment protocols used in the therapy of dogs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20230579     DOI: 10.1111/j.1476-5829.2009.00200.x

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  52 in total

1.  Successful management of doxorubicin overdose and extravasation in a dog with lymphoma.

Authors:  Kristin S Kicenuik; Nicole C Northrup; Dawn M Clarke; Lisa J Bazzle
Journal:  Can Vet J       Date:  2018-10       Impact factor: 1.008

Review 2.  Defining the Value of a Comparative Approach to Cancer Drug Development.

Authors:  Amy K LeBlanc; Christina N Mazcko; Chand Khanna
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

3.  Patient characteristics, prognostic factors and outcome of dogs with high-grade primary mediastinal lymphoma.

Authors:  E L Moore; W Vernau; R B Rebhun; K A Skorupski; J H Burton
Journal:  Vet Comp Oncol       Date:  2017-06-28       Impact factor: 2.613

4.  Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997-2012).

Authors:  Raelene M Wouda; Mairin E Miller; Esther Chon; Timothy J Stein
Journal:  J Am Vet Med Assoc       Date:  2015-06-01       Impact factor: 1.936

5.  NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.

Authors:  Jenna H Burton; Christina Mazcko; Amy LeBlanc; Joseph M Covey; Jiuping Ji; Robert J Kinders; Ralph E Parchment; Chand Khanna; Melissa Paoloni; Sue Lana; Kristen Weishaar; Cheryl London; William Kisseberth; Erika Krick; David Vail; Michael Childress; Jeffrey N Bryan; Lisa Barber; E J Ehrhart; Michael Kent; Timothy Fan; Kelvin Kow; Nicole Northup; Heather Wilson-Robles; Joseph Tomaszewski; Julianne L Holleran; Miguel Muzzio; Julie Eiseman; Jan H Beumer; James H Doroshow; Yves Pommier
Journal:  Clin Cancer Res       Date:  2018-07-30       Impact factor: 12.531

6.  Evaluation of radiographs for the detection of sublumbar lymphadenopathy in dogs.

Authors:  Megan C Murphy; Martin Sullivan; Barbara J Gomes; Ada Kaczmarska; Gawain J C Hammond
Journal:  Can Vet J       Date:  2020-07       Impact factor: 1.008

7.  Consensus recommendations on standardized magnetic resonance imaging protocols for multicenter canine brain tumor clinical trials.

Authors:  Rebecca A Packer; John H Rossmeisl; Michael S Kent; John F Griffin; Christina Mazcko; Amy K LeBlanc
Journal:  Vet Radiol Ultrasound       Date:  2018-03-09       Impact factor: 1.363

8.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

9.  Biodynamic digital holography of chemoresistance in a pre-clinical trial of canine B-cell lymphoma.

Authors:  Honggu Choi; Zhe Li; Hao Sun; Dan Merrill; John Turek; Michael Childress; David Nolte
Journal:  Biomed Opt Express       Date:  2018-04-17       Impact factor: 3.732

10.  Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.

Authors:  Shang-Lin Wang; Jih-Jong Lee; Albert Taiching Liao
Journal:  Can Vet J       Date:  2016-03       Impact factor: 1.008

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.